GCM
BLFS icon

Geneva Capital Management’s BioLife Solutions BLFS Stock Holding History

Geneva Capital Management’s Portfolio BLFS Stock Details BLFS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.4M Sell
582,141
-157,662
-21% -$3.68M 0.38% 67
2026
Q1 		$14.1M Sell
739,803
-63,735
-8% -$1.41M 0.3% 78
2025
Q4 		$19.4M Sell
803,538
-95,493
-11% -$2.5M 0.37% 76
2025
Q3 		$22.9M Sell
899,031
-2,733
-0.3% -$64.8K 0.39% 72
2025
Q2 		$19.4M Buy
901,764
+49,637
+6% +$1.12M 0.33% 77
2025
Q1 		$19.5M Sell
852,127
-614
-0.1% -$16.2K 0.36% 75
2024
Q4 		$22.1M Sell
852,741
-12,525
-1% -$312K 0.38% 74
2024
Q3 		$21.7M Buy
865,266
+965
+0.1% +$22.8K 0.36% 83
2024
Q2 		$18.5M Sell
864,301
-15,914
-2% -$309K 0.34% 81
2024
Q1 		$16.3M Buy
880,215
+5,730
+0.7% +$100K 0.29% 88
2023
Q4 		$14.2M Sell
874,485
-650,906
-43% -$8.3M 0.27% 89
2023
Q3 		$21.1M Sell
1,525,391
-36,052
-2% -$568K 0.44% 73
2023
Q2 		$34.5M Buy
1,561,443
+2,750
+0.2% +$57.9K 0.68% 54
2023
Q1 		$33.9M Buy
1,558,693
+38,640
+3% +$869K 0.69% 54
2022
Q4 		$27.7M Sell
1,520,053
-17,583
-1% -$363K 0.62% 58
2022
Q3 		$35M Buy
1,537,636
+84,435
+6% +$1.81M 0.81% 50
2022
Q2 		$20.1M Sell
1,453,201
-3,455
-0.2% -$50.7K 0.46% 84
2022
Q1 		$33.1M Sell
1,456,656
-32,348
-2% -$852K 0.64% 65
2021
Q4 		$55.5M Buy
1,489,004
+177,875
+14% +$7.63M 0.89% 44
2021
Q3 		$55.5M Buy
1,311,129
+284,432
+28% +$13.7M 0.94% 41
2021
Q2 		$45.7M Sell
1,026,697
-6,398
-0.6% -$225K 0.74% 60
2021
Q1 		$37.2M Buy
+1,033,095
New +$40.8M 0.63% 67

Other funds holding BLFS

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geneva Capital Management's BLFS Position: Q2 2026 in Review

Geneva Capital Management reduced its BioLife Solutions (BLFS) stake by 21% in Q2 2026, selling an estimated $3.68M and leaving 582,141 shares worth $16.4M. The position accounts for 0.38% of the portfolio, ranked #67.

Geneva Capital Management first reported a position in BLFS in Q1 2021 and has held it in 22 quarters since. The position peaked at $55.5M in Q4 2021. 216 funds tracked by Wall St. Rank hold BLFS as of Q2 2026.

  • Geneva Capital Management held 582,141 shares of BioLife Solutions worth $16.4M as of Q2 2026.
  • Geneva Capital Management sold 157,662 BioLife Solutions shares in Q2 2026, an estimated $3.68M.
  • BioLife Solutions made up 0.38% of Geneva Capital Management's portfolio in Q2 2026, its #67 holding.
  • Geneva Capital Management first reported a position in BioLife Solutions in Q1 2021 and has held it in 22 quarters since.
  • Geneva Capital Management's BioLife Solutions position peaked at $55.5M in Q4 2021.
  • 216 funds tracked by Wall St. Rank held BioLife Solutions as of Q2 2026.

Based on Geneva Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.